Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Terminated
Abbott
Phase 3
The primary objective of this study is to assess the overall survival (OS) of oral linifanib
given as monotherapy once daily (QD) compared to sorafenib given twice daily (BID) per
standard of care in subjects with advanced or metastatic HCC.
A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)
Completed
Abbott
Phase 1
The primary objective of this study is to assess the safety and pharmacokinetics of
linifanib, and identify tolerable dose of linifanib (ABT-869) in combination with carboplatin
and paclitaxel in Japanese subjects with advanced or metastatic non-small cell lung cancer
(NSCLC). Secondary objective is to obtain a preliminary efficacy of anti-tumor activity in
the subjects as first-line treatment.
A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)
Completed
AbbVie
Phase 1
The primary objective of this study is to assess the safety and pharmacokinetics of
linifanib, and identify tolerable dose of linifanib (ABT-869) in combination with carboplatin
and paclitaxel in Japanese subjects with advanced or metastatic non-small cell lung cancer
(NSCLC). Secondary objective is to obtain a preliminary efficacy of anti-tumor activity in
the subjects as first-line treatment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
